Pregabalin versus Montelukast in the management of uremic pruritus in hemodialysis patients

Authors

  • Ruba Ahmed Najeeb Department of Pharmacology, Medical College of Baghdad University, Baghdad, Iraq
  • Samara Mowafaq Ali Department of Pharmacology, Medical College of Baghdad University, Baghdad, Iraq

DOI:

https://doi.org/10.31351/vol34iss4pp150-157

Abstract

Many patients with chronic kidney (CKD) disease experience uremic pruritus (UP), which lowers quality of life. The intensity of UP varies and can cause anything from occasional pain to total restlessness during the day or night. this trial aimed to compare the efficacy of pregabalin and montelukast in uremic pruritus among CKD undergoing hemodialysis. For four weeks, this was a randomize prospective- intervention trial. patients with end-stage renal disease, between the ages of 30 and 75, been on hemodialysis at least one year and persistently severe pruritus had been included. Patients were split into Group P (n=25) receiving 50 mg of pregabalin and Group M (n=25) receiving 10 mg of montelukast. Every week, the effectiveness of the medications was evaluated using a numeric rating scale (NRS) and a 5D itch score. Compared to baseline, montelukast and pregabalin reduce 5-D scale (p<0.05). Between the two medications, no noticeable distinctions were seen (p>0.05). the study concluded that montelukast and pregabalin medication, have a positive effect on reducing UP while there were no significant differences observed between the two drugs.

How to Cite

1.
Aljader R, Mowafaq Ali S. Pregabalin versus Montelukast in the management of uremic pruritus in hemodialysis patients. Iraqi Journal of Pharmaceutical Sciences [Internet]. 2025 Dec. 20 [cited 2025 Dec. 21];34(4):150-7. Available from: https://www.bijps.uobaghdad.edu.iq/index.php/bijps/article/view/3924

Publication Dates

Received

2024-06-23

Revised

2024-08-15

Accepted

2024-10-29

Published Online First

2025-12-20

References

Meena BK, Meena O, Meena A, Kumar A. Evaluation of ckd patients for gerd and gastroduodenal ulcerations and their correlation with H. pylori status. journal of cardiovascular disease research. 2024;15(2):11. DOI: 10.4807/jcdr.2024.15.02.174

Noor I.A. Ibraheem MSc cb, PhD RHA, CABMS(uro). MBI. Kidney functions and electrolyte disturbance among Iraqi patients with bladder cancer. J Fac Med Baghdad. 2023;.64(4):4. DOI:https://doi.org/10.32007/jfacmedbagdad.6441985.

Murton M, Goff-Leggett D, Bobrowska A, Garcia Sanchez JJ, James G, Wittbrodt E, et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. Advances in therapy. 2021;38:180-200. DOI:https://doi.org/10.1007/s12325-020-01568-8

Ahmed A. kahdem BSc MCC, AliA.DyabAllawi MBChB FL, Shaymaa Z. Nada BSc PCB, Kismat M. Turki BSc PCC. Neutrophil gelatinase associated lipocalin (NGAL) in early detection of nephropathy in type 2 diabetic Iraqi patients. Fac Med Baghdad 2017;.59:5. DOI:https://doi.org/10.32007/jfacmedbagdad.591170

(Hematology) HAA-RF-P, MSc DDH, Raid A. Al-Rubaye CABM M. Classification of anemia in hemodialysis patients in relation to vascular access and its correlation with hepcidin and ferritin. Fac Med Baghdad. 2016;.58:6. DOI:https://doi.org/10.32007/jfacmedbagdad.582232

Uppal NN, Corona A, Fishbane S. Pruritus in chronic kidney disease. Current opinion in nephrology and hypertension. 2022;31(5):435-41. DOI: 10.1097/MNH.0000000000000824

Ghassan B, Alalsaidissa JNJ, Al-Saedi AJH, Alawchi SN. Relationship of Pruritus with Biochemical and Haematological Parameters in Haemodialysis Patients (A Single Center Study). Fac Med Baghdad. 2015;57(4):306-11. DOI:https://doi.org/10.32007/jfacmedbagdad.574396

Agarwal P, Garg V, Karagaiah P, Szepietowski JC, Grabbe S, Goldust M. Chronic kidney disease-associated pruritus. Toxins. 2021;13(8):527. DOI:https://doi.org/10.3390/toxins13080527

Wang CC, Wu HH, Ponnusamy A, Pye I, Woywodt A. Pruritus in chronic kidney disease: an update. Allergies. 2022;2(3):87-105. DOI:https://doi.org/10.3390/allergies2030009

Alkhafaji MS, Al-Mayahi AM. Effectiveness of an Educational Program on Hemodialysis Patients’ knowledge about Uremic Pruritus. Pakistan Heart Journal. 2023;56(2):397-406.

Kim D, Pollock C. Epidemiology and burden of chronic kidney disease-associated pruritus. Clin Kidney J. 2021;14(3):i1-i7. DOI:https://doi.org/10.1093/ckj/sfab142

Santos-Alonso C, Martín MM, Villanueva RS, García LÁ, Gallardo MAV, Rubio MAB, et al. Pruritus in dialysis patients. Review and new perspectives. Nefrología (English Edition). 2022;42(1):15-21. DOI:https://doi.org/10.1016/j.nefroe.2022.02.004

Ravindran A, Kunnath RP, Sunny A, Vimal B. Comparison of safety and efficacy of pregabalin versus gabapentin for the treatment of uremic pruritus in patients with chronic kidney disease on maintenance haemodialysis. Indian Journal of Palliative Care. 2020;26(3):281. DOI:10.4103/IJPC.IJPC_212_19

Prasad B, Gagarinova M, Sharma A. Five things to know about pruritus in patients on dialysis. Canadian Journal of Kidney Health and Disease. 2023;10. DOI:https://doi.org/10.1177/20543581221149620

Cheng A-Y, Wong L-S. Uremic pruritus: from diagnosis to treatment. Diagnostics. 2022;12(5):1108. DOI:https://doi.org/10.3390/diagnostics12051108

Baidya DK, Agarwal A, Khanna P, Arora MK. Pregabalin in acute and chronic pain. Journal of Anaesthesiology Clinical Pharmacology. 2011;27(3):307-14. DOI: 10.4103/0970-9185.83672

Kassim M.Sultan MBChB M, FRCP (Glasg). Montelukast As An Add On Therapy In Asthma As Compared To Its Use In Asthma Associated With Concomitant Rhinitis Symptoms Fac Med Baghdad. 2011; 53:4. DOI:https://doi.org/10.32007/jfacmedbagdad.532847

Gao C-q, Zhou J-j, Tan Y-y, Tong C-j. Effectiveness of montelukast for uremic pruritus in hemodialysis patients: a protocol for systematic review and meta-analysis. Medicine. 2020;99(46) :e23229. DOI: 10.1097/MD.0000000000023229

Al-Hamdani FY. Comparative clinical evaluation of ketotifen and montelukast sodium in asthmatic Iraqi patients. Saudi Pharmaceutical Journal. 2010;18(4):245-9. DOI:https://doi.org/10.1016/j.jsps.2010.07.001

Tesfaye BA, Hailu HG, Zewdie KA, Ayza MA, Berhe DF. Montelukast: the new therapeutic option for the treatment of epilepsy. Journal of Experimental Pharmacology. 2021:23-31. DOI:http://doi.org/10.2147/JEP.S277720

Hong W-p, Lee Y-J. The association of dialysis adequacy, body mass index, and mortality among hemodialysis patients. BMC nephrology. 2019;20:1-8. DOI: https://doi.org/10.1186/s12882-019-1570-0

Zhou X, Guo Y, Luo Y. The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients. Renal failure. 2021;43(1):599-605. DOI:https://doi.org/10.1080/0886022X.2021.1903927

John feehally jf, marcello tonelli, richard j. johnson. comprehensive clinical nephrology. sixth editioned: elsevier; 2019. 936-7 p.

Tuchinda P, Kulthanan K, Chularojanamontri L, Rujitharanawong C, Subchookul C, Trakanwittayarak S. The validity and reliability of the Thai-version of 5-D itch scale. Asian Pacific Journal of Allergy and Immunology. 2022;40(3):254-62. DOI:https://doi.org/10.12932/ap-100120-0738

Fishbane S, Mathur V, Germain MJ, Shirazian S, Bhaduri S, Munera C, et al. Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients. Kidney international reports. 2020;5(5):600-10. DOI:https://doi.org/10.1016/j.ekir.2020.01.006

Yoosefinejad AK, Karjalian F, Momennasab M, Jahromi SE. Reliability and validity of the Persian version of 5-D itching scale among patients with chronic kidney disease. BMC nephrology. 2021;22(1):1-8. DOI:https://doi.org/10.1186/s12882-020-02220-x

Vernon MK, Swett LL, Speck RM, Munera C, Spencer RH, Wen W, et al. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus. Journal of patient-reported outcomes. 2021;5(1):1-12. DOI:https://doi.org/10.1186/s41687-021-00404-z

Wen-Jing Z, Rui-Zhi T, Si-Yuan H, Xiao-Mei D, Qiong-Dan H, Xiao-Qian Z, et al. Data independent acquisition reveals in-depth serum proteome changes in uremic pruritus. Frontiers in Physiology. 2024;15:1287072. DOI:https://doi.org/10.3389/fphys.2024.1287072

Elhag S, Rivas N, Tejovath S, Mustaffa N, Deonarine N, Hashmi MA, et al. Chronic kidney disease-associated pruritus: a glance at novel and lesser-known treatments. Cureus. 2022;14(1). DOI:: 10.7759/cureus.21127

Mehdi Mahmudpour JR, 2 Qanbar Ali Raiss Jalali,1, Maryam Pakfetrat SEZ, 1, Sagheb1 MM. Therapeutic Effect of Montelukast for Treatment of Uremic Pruritus in Hemodialysis Patients. Iranian Journal of Kidney Diseases. 2017; 11:50-5.

Chao-qing Gao M, Jia-jun Zhou, MD, Ya-yin Tan, MM, Chang-jun Tong, MM. Effectiveness of montelukast for uremic pruritus in hemodialysis patients.Medicine. 2020; 99(46):1-3. DOI: 10.1097/MD.0000000000023229

Martin CE, Clotet-Freixas S, Farragher JF, Hundemer GL. Have we just scratched the surface? A narrative review of uremic pruritus in 2020. Canadian Journal of Kidney Health and Disease. 2020;7:1-14 DOI:https://doi.org/10.1177/2054358120954024

El Mulla KF, Khalifa DE, Gawish RI, Eldeeb ME. Phototherapy versus pregabalin in treatment of chronic kidney disease associated pruritus: randomized controlled study. Journal of the Egyptian Women’s Dermatologic Society. 2023;20(2):81-9. DOI: 10.4103/jewd.jewd_50_22

Boehlke C, Joos L, Coune B, Becker C, Meerpohl JJ, Buroh S, et al. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database of Systematic Reviews. 2024(2). DOI: https://doi.org/10.1002/14651858.CD008320.pub4

Downloads

Published

2025-12-20

Issue

Section

Article